Relmada Therapeutics (RLMD) Tops Q2 EPS by 10c

Relmada Therapeutics (NASDAQ: RLMD) reported Q2 EPS of ($0.30), $0.10 better than the analyst estimate of ($0.40).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Oracle (ORCL) call put ratio 2.3 calls to 1 put with a focus on October calls into quarter results
• Casey's General Stores (CASY) call put ratio 1.3 calls to 1 put into the quarter results
• Roivant Sciences (ROIV) PT Raised to $52 at Jefferies